Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple IV drip may prevent painful complication after common bile duct procedure

NCT ID NCT06260878

Prevention Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a short course of intravenous Ringer's lactate fluid around the time of an ERCP procedure can prevent pancreatitis, a common and serious side effect. Researchers will enroll 505 adults aged 18-75 who are having their first ERCP. Participants will receive the IV fluid and be monitored for signs of pancreatitis the next day.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intravenous Ringer's lactate
What this could lead to
If successful, this could provide a simple, low-cost way to prevent a common and serious complication of ERCP, reducing hospital stays and improving patient outcomes.
What could go wrong
This is a single-center trial with 505 participants, so results may not apply to all patients. The benefit may be small or absent, and there is a risk of fluid overload in some individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 505 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. age 18-75 years (due to higher likelihood of undiagnosed cardiac disease or renal insufficiency in patients \>75 years of age) 2. ability to give informed consent 3. native major papillary anatomy 4. ability and willingness to obtain bloodwork the day after ERCP Exclusion Criteria: 1. prior ERCP with sphincterotomy and/or sphincteroplasty 2. confirmed or suspected cholangitis or sepsis 3. confirmed pancreatitis, hyperlipasemia, or hyperamylasemia within the preceding 7 days 4. NYHA Class II or greater heart failure 5. active pulmonary edema 6. myocardial infarction or ischemia within the preceding 3 months 7. renal insufficiency with CrCl \< 40 mL/minute 8. CPT Class B or C cirrhosis and/or end-stage liver disease 9. room air oxygen saturation \<90% or requirement of home O2 10. hypernatremia with Na+ ≥ 150 mEq/L or Na+ \<130 mEq/L 11. uncontrolled hypertension or hypotension 12. pregnant status

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-ercp acute pancreatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute pancreatitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-ercp acute pancreatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peter Lougheed Centre

    RECRUITING

    Calgary, Alberta, T1Y 6J4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.